Investors of Pacira BioSciences Face Securities Fraud Lawsuit as Rosen Law Firm Seeks Lead Plaintiffs

Opportunity for Pacira BioSciences Investors in Securities Fraud Case

The Rosen Law Firm has recently put out a call for investors who purchased shares in Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023, and August 8, 2024, to join a pending class action lawsuit alleging securities fraud. With a critical deadline set for March 14, 2025, interested parties are encouraged to take action as the chance to lead the case may slip away.

The Class Period and Your Rights

If you bought Pacira securities during the specified period, you may be eligible to participate in this class-action litigation without incurring any upfront costs, thanks to a contingency fee structure established by the law firm. The implication here is that if the suit is unsuccessful, you won’t owe the law firm anything — a noteworthy point for those concerned about potential financial impacts.

Next Steps for Interested Investors

To join this class action initiative, you can visit the website Rosen Legal, or reach out via phone to Phillip Kim, Esq. at 866-767-3653, or send an email to [email protected] This legal action is already in progress, and those desiring to serve as lead plaintiffs must file their motion by the March deadline.

Why Choose Rosen Law Firm?

Rosen Law is a highly regarded global firm specializing in investor rights and securities litigation. Their credibility stems from a significant track record of successful settlements; notably, they secured the largest securities settlement against a Chinese company at one time. They were ranked number one for securities class action settlements in 2017 and have consistently maintained a top-four position since 2013. In 2019, they recovered over $438 million on behalf of investors, asserting their capability to effectively fight for the rights of those affected by potentially misleading corporate practices.

Case Background

The lawsuit posits that the statements made by Pacira within the specified class period were misleading, as they fostered an unfounded sense of security regarding the company’s patent protections for their product, Exparel. This misinformation allegedly led investors to believe that Pacira could massively expand the marketing and sales of Exparel, crucially impacting the company’s projected growth.

However, it has come to light that the optimism surrounding the company's patent, referred to as the '495 patent, was not as robust as suggested. Key court rulings, such as the one from the New Jersey District Court regarding Pacira's patent in another case, have pointed out vulnerabilities that contradict the company’s public affirmations about its patent protections. These revelations, once disclosed to the public, resulted in financial damages for investors who had acted on the previously held assumptions of security in the company's innovative protections.

Legal Representation and Class Member Information

It’s crucial for potential class members to understand that no class has been certified yet. Joining the class action does not automatically confer representation without retaining a counsel. Investors can either choose their legal representation or opt to remain passive in this particular class action—either way, their ability to benefit from any recovery in the future is not predicated on being a lead plaintiff.

Keeping Updated

For ongoing updates regarding this case and other related news, investors can follow the Rosen Law Firm on social media platforms such as LinkedIn, Twitter, and Facebook.

In conclusion, time is of the essence for investors in Pacira BioSciences to engage with Rosen Law Firm and explore their eligibility to join this growing case for potential compensation related to securities fraud. This is a crucial window for affected investors to take accountable steps for their financial well-being.